Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

Inclusion Criteria: * Elevated PSA (4.0-10.0 ng/ml) or abnormal digital rectal exam with PSA of 2.00-10.00 ng/ml as indicated in the patient's lab report. * Patients must be biopsy naïve, confirmed with patient or medical record. * Patients must be male, ≥18 and ≤ 89 years of age. * Patient must have a life expectancy ≥10 years, determined by PI. * Patients must exhibit an ECOG performance status of 0-2, as noted in their medical record. Exclusion Criteria: * Patients who are on a 5-α-reductase inhibitor within 12 months of enrollment, as confirmed by medical record. * Patients who have had a prostate infection within 1 month of enrollment, as confirmed by medical record. * Patients who are receiving or who received prostate cancer treatment (e.g., androgen deprivation therapy, surgery, radiation therapy or adjuvant/neoadjuvant therapy with investigational drugs) per their medical record. * Patients who've had an invasive urological procedure within 1 month of enrollment, as confirmed by their medical record and patient reporting. * Patients with no access to the rectum for a transrectal ultrasound, as determined by the Urologist. * Patients with a contraindication to magnetic resonance imaging (MRI). * Vulnerable populations: Prisoners or adult men \>89 years old.